Earnshaw S, McDade C, Marriott R, Daane L, Le Coent V, Yang J. Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing. Poster presented at the 2021 31st International Society of Blood Transfusion (ISBT) Virtual Conference; June 2, 2021. [abstract] Vox Sang. 2021; 116(Suppl 1):167.
Beyhaghi H, Zimmer L, McDade C, Purser M, Blanc E, Pavlov V, Earnshaw S. The cost-effectiveness of blood-based brain biomarkers for screening adults with mild traumatic brain injury. Poster presented at the 2020 Digital 33rd European Society of Intensive Care Medicine (ESICM) Congress; December 6, 2020. [abstract] Intensive Care Med Exp. 2020; 8(Suppl 2):000107.
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. The economic burden of Crohn's disease in Europe: findings from a systematic literature review. Poster presented at the 2019 27th United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:906.
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.
Graham J, Xuan D, Luthra R, Borker R, Earnshaw SE, Lim J. Budget impact analysis of afatinib for the first-line treatment of metastatic non-small cell lung cancer patients with epidermal growth factor receptor exon 19 deletion mutations in a U.S. health plan. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S30.
Qin L, Chen Y, Lesher B, Qifa L, Charbonneau C, Earnshaw SR, McDade CL, Mao N, Gao X. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected aspergillus invasive fungal infections in China. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A237.
Patel J, Coleman A, Wilson M, McDade C, Carr S, Earnshaw S. Budgetary impact on a U.S. health plan after adopting umeclidinium/vilanterol (UMEC/VI) for the management of moderate-to-severe COPD. Poster presented at the 2015 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 7, 2015. San Diego, CA. [abstract] J Manag Care Pharm. 2015 Apr 7; 21(4a):S55.
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Hicks K, Earnshaw S, McDade C, Shaw JW, Cifaldi MA. Benefit-risk analysis of adalimumab and alternative treatments for moderate to severe rheumatoid arthritis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A439-40.
Mladsi D, Herring WL, Earnshaw S. Cost-effectiveness analysis in personalized medicine: general hypotheses and corresponding decision tree structures for screening, diagnostic, predictive, prognostic, surveillance, and monitoring tests. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A168-9.
Earnshaw SR, McDade CL, Zanotti G, Farkouh R, Strutton D. Cost-effectiveness of 2+1 dosing of 13-valent pneumococcal conjugate vaccine compared with 2+1 dosing of 10-valent conjugate vaccine in preventing pneumococcal disease in Canada. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A275.
Hicks KA, Karve S, Vlahiotis A, Frazee S, Tian Y, Earnshaw SR. Estimation of increases in direct medical expenditures associated with medication nonadherence and potential savings from increased adherence. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A343-4.
Mladsi D, Earnshaw S, Ronquest NA, Keith M. The threshold pricing model: not just another cost-effectiveness model. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A332.
Mladsi D, Earnshaw S, Akashi-Ronquest N, Keith M. Proposed methods for conducting sensitivity analyses on threshold-derived estimates of value-based price and product profiles of early stage drugs. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A333.
Earnshaw S, Pignone M, Fendrick AM, Scheiman J, McDade C. Cost-effectiveness of proton pump inhibitors for prevention of gastrointestinal adverse events when using aspirin for primary cardiovascular prevention. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A166.
Jackson D, Earnshaw S, Farkouh RA, Schwamm LH. Cost-effectiveness of perfusion imaging with computed tomography to identify patients for intravenous thrombolysis: a hospital perspective. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A175.
Kauf T, Davis KL, Earnshaw S, Davis EA, Watson ME. Spillover adherence effects of fixed-dose combination HIV therapy. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A430.
Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.
Papanicolaou S, Kontodimas S, Syriopoulou E, Tsolia M, Theodoridou M, Kremastinou J, Tzanakaki G, Strutton D, Hwang S, Earnshaw SR. Clinical and economic benefits of national immunization with the 13-valent compared to 7- and 10-valent pneumococcal conjugate vaccines in Greece. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A423-4.
Whillans F, Kwan H, Strutton DR, Earnshaw SR, Farkouh RA. Cost-effectiveness of 13-valent and 10-valent pneumococcal conjugate vaccination relative to 7-valent pneumococcal conjugate vaccination in Canada. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France. [abstract] Value Health. 2009 Oct; 12(7):A425.
Earnshaw SR, Jackson DL, Farkouh RA, Schwamm LH. Cost-effectiveness of MRI-based selection of patients for intravenous thrombolysis. Poster presented at the 2009 International Stroke Conference; February 2009. San Diego, CA. [abstract] Stroke. 2009 Apr; 40(4):E192-3.
Graham CN, Earnshaw SR, Raymond V. Cost-effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis in Canada. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A98.
Graham JB, Earnshaw SR, Castelli-Haley J, Oleen-Burkey M, Johnson KP. Cost-effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis in the presence of long-term clinical evidence. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 24, 2007. [abstract] Value Health. 2007 Nov; 10(6):A381.
Earnshaw SR, McDade CL, Mangel AW, Baran RW. Cost-effectiveness of lubiprostone in a managed care population with chronic idiopathic constipation. Poster presented at the 2007 ACG Annual Meeting; September 2007. [abstract] Am J Gastroenterol. 2007 Sep; 102(S2):S449-50.
Earnshaw SR, Wilson MR, Joshi AV. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage over a two-year managed care enrollment period. Poster presented at the 2007 ISPOR 12th Annual International Meeting; May 22, 2007. [abstract] Value Health. 2007 May; 10(2):A182. Previously presented at the 2006 International Stroke Conference.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Earnshaw SR, Wilson MR, Joshi AV. Budgetary impact analysis of recombinant activated factor vii in the treatment of intracerebral hemorrhage: a US health plan perspective. Poster presented at the 2006 ISPOR 9th Annual European Congress; October 31, 2006. [abstract] Value Health. 2006 Nov; 9(6):A329.
Earnshaw SR, Graham CN, Amonkar MM, Barr C. The cost-effectiveness of ibandronate in the treatment of postmenopausal osteoporosis in the US. Poster presented at the 2006 ISPOR 11th Annual International Meeting; May 20, 2006. Philadelphia, PA. [abstract] Value Health. 2006 May; 9(3):A163.
Earnshaw SR, Javitt JC, Graham CN, Brogan AJ, Zlateva GP, Shah S, Adamis AP. Modeling treatments for subfoveal choroidal neovascularization secondary to age-related macular degeneration: cost-effectiveness methods. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6):A179.
Earnshaw SR, Javitt JC, Zlateva GP, Pleil AM, Graham CN, Brogan AJ, Shah S, Adamis AP. Cost-effectiveness model for age-related macular degeneration: comparing early and late Macugen® treatment. Poster presented at the 2005 ISPOR 8th Annual European Congress; November 10, 2005. Florence, Italy. [abstract] Value Health. 2005 Nov; 8(6).
Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.
Earnshaw SR, Krishnan A, Hogue SL, Williams JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):267.
Dombeck M, Earnshaw SR, Candrilli SD, Xuan J, Bakst A, Kirsch JM. Modeling antibiotic efficacy by infectious agent and probability of resistance. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress; November 2001. [abstract] Value Health. 2001 Sep; 4(6):427.
Alexeyeva I, Mauskopf JA, Earnshaw SR, Gibson JP, Ascher-Svanum H, Ramsey J. A model comparing olanzapine and ziprasidone in patients with schizophrenia. Poster presented at the 2001 ISPOR 6th Annual International Meeting; May 2001. [abstract] Value Health. 2001 Sep; 4(2):148-9.